---
title: "Merck KGaA (0O14) Gets a Buy from UBS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285522532.md"
description: "UBS analyst Matthew Weston has maintained a Buy rating on Merck KGaA, setting a price target of €150.00. Weston, a 4-star analyst with a 69.52% success rate, also covers other healthcare stocks. Previously, J.P. Morgan's Richard Vosser also rated Merck KGaA as a Buy, while Deutsche Bank maintained a Hold rating on April 30."
datetime: "2026-05-07T09:15:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285522532.md)
  - [en](https://longbridge.com/en/news/285522532.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285522532.md)
---

# Merck KGaA (0O14) Gets a Buy from UBS

UBS analyst Matthew Weston maintained a Buy rating on Merck KGaA today and set a price target of €150.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Weston is a 4-star analyst with an average return of 9.4% and a 69.52% success rate. Weston covers the Healthcare sector, focusing on stocks such as AstraZeneca, Roche Holding AG, and Sanofi.

In addition to UBS, Merck KGaA also received a Buy from J.P. Morgan’s Richard Vosser in a report issued on May 5. However, on April 30, Deutsche Bank maintained a Hold rating on Merck KGaA (LSE: 0O14).

### Related Stocks

- [MKKGY.US](https://longbridge.com/en/quote/MKKGY.US.md)
- [MRK.DE](https://longbridge.com/en/quote/MRK.DE.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [DB.US](https://longbridge.com/en/quote/DB.US.md)
- [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md)
- [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md)

## Related News & Research

- [J.P. Morgan Sticks to Their Buy Rating for Merck KGaA (0O14)](https://longbridge.com/en/news/285217857.md)
- [Merck KGaA Non-GAAP EPS of €8.34, revenue of €21.1B; introduces FY26 outlook](https://longbridge.com/en/news/277906382.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields](https://longbridge.com/en/news/286913304.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)